In conclusion, SOX30 is significantly associated with histologic type and clinical stage in NSCLC patients, and heightened SOX30 represents an independent prognostic factor for increased survival time of ADC patients or the ones who are at clinical stage II, with positive lymph nodes, at histological grade 2 or grade 3. This evidence concerns the gene SOX30 and non-small cell lung carcinoma.